Transmission Dynamics of Carbapenemase Genes in CREC: Molecular Epidemiology from Guangdong Hospitals

Study Background and Research Question

Carbapenem-resistant Enterobacteriaceae (CRE) present a significant public health threat, with Enterobacter cloacae ranking as the third most frequently detected CRE species in China. The COVID-19 pandemic, characterized by increased antibiotic use and healthcare disruptions, has further complicated antimicrobial resistance (AMR) patterns and transmission dynamics. However, detailed molecular epidemiology on how carbapenemase-encoding genes (CEGs) spread within CREC populations, especially in the context of the pandemic, has been limited. Addressing this gap, Chen et al. (2025) investigated the prevalence, genetic context, and transmission of CEGs in 54 CREC isolates from eight teaching hospitals in Guangdong Province between December 2022 and June 2024. The central research question was: How are carbapenemase-encoding genes distributed and transmitted among CREC clinical isolates during the COVID-19 pandemic?

Key Innovation from the Reference Study

The primary innovation of this study lies in its comprehensive, multi-hospital analysis of CEGs in CREC, explicitly linking gene location (plasmid vs. chromosome), mobile genetic elements, and transmission capacity with epidemiological data. Notably, the research provides quantitative insights into the dissemination rates of major CEGs (especially blaNDM-1), the success of horizontal gene transfer, and the clinical and demographic correlates of CEG prevalence. By integrating molecular genetics, conjugation assays, and epidemiological profiling, the study offers a detailed map of resistance gene ecology during a critical period of heightened AMR risk.

Methods and Experimental Design Insights

The study analyzed 54 non-redundant CREC isolates collected across eight tertiary teaching hospitals over an 18-month period. Key methodological elements include:

• Plasmid Elimination and Localization: Variable temperature Sodium Dodecyl Sulfate (SDS) treatment was used to distinguish plasmid from chromosomal gene carriage, followed by PCR amplification targeting blaNDM-1, blaIMP, and blaKPC-2 genes.
• Resistance Profiling: The broth microdilution method assessed susceptibility to imipenem, cefepime, gentamicin, ceftazidime/avibactam, ciprofloxacin, and levofloxacin.
• Conjugation Experiments: Plasmid-mediated transferability of CEGs was quantified via conjugation assays and PCR confirmation in recipient strains.
• Mobile Genetic Element Analysis: PCR was used to identify six types of mobile elements, with special focus on ISEcp1.
• Genotyping: Enterobacterial Repetitive Intergenic Consensus-PCR (ERIC-PCR) and NTSYS software clustered isolates into genotype groups, correlating genetic diversity with clinical and demographic data.

The rigorous combination of molecular, phenotypic, and epidemiological methods enabled high-resolution tracking of CEGs in the hospital setting.

Core Findings and Why They Matter

The study's central findings have significant implications for antimicrobial resistance research:

• High Prevalence and Plasmid Localization of CEGs: 85.19% of CREC isolates harbored carbapenemase-encoding genes, with 79.63% carrying blaNDM-1 (33.33% on both chromosome and plasmid; 46.30% on plasmid only). Only a minority carried blaIMP or both blaNDM-1 and blaKPC-2.
• Multidrug Resistance Patterns: CEG-positive strains exhibited significantly higher resistance rates to a broad spectrum of antibiotics, including beta-lactams and fluoroquinolones, underscoring the clinical challenge of treating such infections (Chen et al., 2025).
• Efficient Horizontal Gene Transfer: Conjugation experiments demonstrated a 95.65% success rate for CEG transfer, with blaNDM-1 and blaIMP showing the highest mobility. This supports the critical role of plasmids in the rapid dissemination of carbapenemase genes.
• Mobile Genetic Elements as Vectors: Six mobile genetic element types were identified, with ISEcp1 being the most prevalent (87.04% of isolates). Many strains harbored multiple mobile elements, increasing the risk of gene mobilization and recombination.
• Molecular Epidemiology: Genotyping revealed 17 distinct CREC clusters, with dominant types present in multiple hospitals and departments, indicating cross-institutional transmission.
• Demographic and Clinical Correlates: Higher CEG detection rates were observed in male and elderly patients, respiratory medicine departments, and sputum samples, highlighting patient groups at elevated risk of CREC acquisition.

These findings clarify the mechanisms underpinning the rise of carbapenem-resistant infections and underscore the urgent need for targeted surveillance and infection control, especially in vulnerable patient populations.

Comparison with Existing Internal Articles

Several internal articles provide complementary perspectives and practical guidance on modeling antimicrobial resistance and transmission dynamics using laboratory tools and clinical isolates:

• Transmission Dynamics of Carbapenemase Genes in CREC Hospitals echoes the reference study's emphasis on the dominant role of plasmid-mediated blaNDM-1 and high multidrug resistance. Both works reinforce the importance of mapping gene transfer rates for effective AMR surveillance.
• Cefotaxime in Antimicrobial Resistance Research: Protocols & Pitfalls discusses how third-generation cephalosporin antibiotics, such as Cefotaxime, are used to model and dissect resistance mechanisms in both Gram-positive and Gram-negative bacteria. This is relevant to the current study, where cephalosporin resistance was notably higher in CEG-positive CREC, providing a practical link between molecular epidemiology and laboratory modeling workflows.
• For detailed laboratory workflows, Cefotaxime: Advanced Workflows for Antimicrobial Resistance Research offers best practices for resistance mechanism profiling, supporting researchers aiming to replicate or extend similar studies.

These resources collectively highlight the translational value of combining molecular studies with robust in vitro infection models, particularly when investigating beta-lactam antibiotic mechanisms and resistance dynamics.

Limitations and Transferability

The study's multi-hospital design strengthens the generalizability of its findings within Guangdong Province. However, several important limitations are noted:

• Geographical Scope: Results are specific to eight teaching hospitals in one Chinese province, and may not reflect national or international trends due to local antibiotic stewardship practices and patient populations.
• Temporal Context: The study period overlaps with the COVID-19 pandemic, potentially amplifying antibiotic usage and transmission opportunities. Patterns may shift post-pandemic.
• Lack of Clinical Outcome Data: While genotypes and resistance profiles are well characterized, the clinical outcomes for infected patients are not reported, limiting the translational impact for infection control policy.
• Focus on Select Antibiotics: Resistance to other clinically important agents (e.g., newer cephalosporins, carbapenem combinations) was not evaluated.

Nonetheless, the methods and findings are highly transferable to other research groups aiming to study the epidemiology and molecular genetics of AMR in hospital settings, especially for modeling horizontal gene transfer and multidrug resistance.

Protocol Parameters

• Sample collection period: December 2022 to June 2024; enables assessment over pandemic and post-pandemic transitions.
• Plasmid elimination protocol: Variable temperature SDS treatment, followed by targeted PCR for gene localization.
• Antibiotic susceptibility testing: Broth microdilution for imipenem, cefepime, gentamicin, ceftazidime/avibactam, ciprofloxacin, levofloxacin.
• Conjugation assay: Use donor and recipient strains with antibiotic selection to quantify plasmid-mediated gene transfer (95.65% success rate for CEGs in this study).
• Genotyping: ERIC-PCR and software clustering; correlate with epidemiological metadata for transmission mapping.
• Mobile genetic element analysis: PCR for ISEcp1 and other insertion sequences; assess co-occurrence for recombination risk.
• Cefotaxime resistance modeling: When simulating Gram-negative and Gram-positive infection models or beta-lactam mechanism studies, use freshly prepared Cefotaxime solutions and avoid long-term storage, as recommended by the product information.

Research Support Resources

Researchers investigating antimicrobial resistance and gene transfer in hospital pathogens can leverage validated workflows and protocols described in the reference study and internal articles. For experimental modeling, Cefotaxime (SKU BA1012) from APExBIO offers a third-generation cephalosporin antibiotic with robust activity against both Gram-positive and Gram-negative bacteria, suitable for resistance mechanism and infection model studies. Ensure to prepare solutions fresh and maintain recommended storage conditions to preserve compound efficacy in AMR research contexts.